🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› UK
Clinical trial register · United Kingdom · industry-sponsored

Industry-sponsored studies with a UK investigative site

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 2847 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 22 Sep 2026, 03:15 UTC
2847
Studies in scope
industry-sponsored, all four open statuses
1382
Recruiting now
open to new participants
542
Lead sponsors
across recruiting studies
Top sites
London 2004 Manchester 672 Birmingham 470 Glasgow 437 Cambridge 416
Narrow the register
Recruitment status
Phase
Lead sponsor
AstraZeneca195 Merck Sharp & Dohme LLC116 Hoffmann-La Roche105 Novartis Pharmaceuticals97 Janssen Research & Development, LLC93
Site city
London2004 Manchester672 Birmingham470 Glasgow437 Cambridge416
All 426 cities
Target enrolment
to
2847 of 2847 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy
NCT07023614Non-obstructive Hypertrophic Cardiomyopathy
Imbria Pharmaceuticals, Inc.
Phase 2
165
London, Glasgow, Oxford
2025-10-06
Recruiting
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722Crohn Disease
Janssen Research & Development, LLC
Phase 2/3
1,092
Birmingham, Cambridge, Glasgow, Greater Manchester, London, Rainhill, Stockport
2025-10-03
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Pfizer
Phase 2/3
982
Cambridge, London, Edinburgh, Liverpool
2025-10-03
Active, closed
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
NCT07033481Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
EIP Pharma Inc
Phase 2
20
Cambridge, Newcastle upon Tyne
2025-10-02
Recruiting
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Novo Nordisk A/S
Phase 3
1,280
London, Manchester, Bellshill, Birmingham, Cardiff, Liverpool
2025-10-02
Recruiting
CALM Study: Can A Prebiotic Fibre bLend Improve Stress, Mood, and Anxiety?
NCT07201909Stress
Myota GmbH
Not applicable
156
London
2025-10-02
Recruiting
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
NCT07184931Crohn's Disease
Sanofi
Phase 3
980
London
2025-10-01
Recruiting
AI-Driven Early Detection of Skin Cancer
NCT07144306Skin Cancer Melanoma
Nuvana Healthcare LTD
Observational
100
London
2025-10-01
By invitation
A Long-Term Study of Navenibart in Participants With Hereditary Angioedema
NCT07204938Hereditary Angioedema (HAE)
Astria Therapeutics, Inc.
Phase 3
145
Bristol, Cambridge, Frimley, Hampstead, London, Plymouth
2025-10-01
Recruiting
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
NCT06745908NSCLC Stage IV
ImmunityBio, Inc.
Phase 3
507
Belfast, Truro, Bodelwyddan, Cardiff, London, Southampton, Edinburgh, Guildford
2025-10-01
Recruiting
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
NCT07196748Colitis, Ulcerative
Janssen Research & Development, LLC
Phase 3
882
Cambridge, Edinburgh, Greater Manchester, London, Rainhill, Sheffield, Stockport
2025-10-01
Recruiting
Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
NCT07181161Metastatic Prostate Cancer
AstraZeneca
Phase 1/2
283
Cambridge, London, Plymouth, Sutton
2025-10-01
Recruiting
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
NCT07192614Prostate Cancer
AstraZeneca
Phase 1/2
52
Cambridge, Manchester
2025-09-30
Recruiting
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
NCT07106762Urothelial Cancer
Bristol-Myers Squibb
Phase 2/3
470
Glasgow, London, Sheffield
2025-09-30
Recruiting
A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1
NCT07179640Hypophosphatasia (HPP)
Alesta Therapeutics
Phase 1/2
120
Leeds
2025-09-30
Recruiting
Evaluating an Audiology Text-Message Protocol to Support Hearing Aid Use in NHS Adult Audiology Patients
NCT07146607Hearing Loss
WSAUD A/S
Not applicable
70
Nottingham, Sunderland, Wigan
2025-09-30
Recruiting
Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
NCT07204275Primary Membranous Nephropathy
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Derby, Doncaster, Edinburgh, London, Wolverhampton
2025-09-30
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
Pfizer
Phase 3
680
London, Manchester
2025-09-29
Recruiting
A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis
NCT06865417Ulcerative Colitis
Alfasigma S.p.A.
Phase 3
80
Bristol, Glasgow, Liverpool, London, Newcastle, Sheffield
2025-09-29
Recruiting
A Study Evaluating the Safety and Efficacy of MINIject S+ in Subjects With Open Angle Glaucoma
NCT07009236Glaucoma
iSTAR Medical
Not applicable
60
Colchester, Grimsby, Liverpool, London
2025-09-29
Recruiting
A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)
NCT07161544Stargardt Disease
AAVantgarde Bio Srl
Phase 1/2
75
London
2025-09-29
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT06979336Ulcerative Colitis
Genentech, Inc.
Phase 2
224
London, Liverpool, Oxford, Cambridge
2025-09-29
Recruiting
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
NCT07028853Metastatic Castration Sensitive Prostate Cancer (mCSPC), Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Pfizer
Phase 3
1,000
Blackburn, Cardiff, Plymouth, Torquay, London, Maidstone, Edinburgh, Manchester
2025-09-28
Recruiting
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
NCT07190196Immunoglobulin G4 Related Disease
Sanofi
Phase 3
124
Norwich
2025-09-26
Recruiting
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
NCT07007312Acute Myeloid Leukemia (AML)
Kura Oncology, Inc.
Phase 3
1,300
London
2025-09-26
Recruiting
A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)
NCT07133633Radiographic Axial Spondyloarthritis
Merck Sharp & Dohme LLC
Phase 2
315
Norwich, Bath, Barnet, Bradford
2025-09-26
Active, closed
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
NCT07159763Influenza
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
10,000
Aberdeen, Bristol, High Wycombe, Peterborough, Truro, Edinburgh, Birmingham, Blackpool
2025-09-25
Recruiting
A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
NCT07123454B-cell Non-Hodgkin Lymphoma
AstraZeneca
Phase 1/2
91
London, Newcastle upon Tyne
2025-09-24
Recruiting
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
NCT06760546Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia, Optic Nerve Hypoplasia
Rhythm Pharmaceuticals, Inc.
Phase 3
39
London, Birmingham, Hull
2025-09-23
Recruiting
Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension
NCT07115953Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases
Medtronic Vascular
Not applicable
130
Oxford
2025-09-22
Recruiting
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
NCT07053423Chronic Obstructive Pulmonary Disease
Sanofi
Phase 4
218
Newcastle upon Tyne, Southampton, Leicester, Bradford
2025-09-22
Recruiting
Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
NCT07181109High Risk Cardiovascular Disease, Hypertension, High Cardiovascular Risk
Alnylam Pharmaceuticals
Phase 3
11,000
Ashburton, Belfast, Bellshill, Birmingham, Bristol, Bury St Edmunds, Cambridge, Cardiff
2025-09-22
Recruiting
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT07111520Non-small Cell Lung Cancer
BioNTech SE
Phase 1/2
880
London, Newcastle upon Tyne, Sutton
2025-09-22
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967Plaque Psoriasis
Bristol-Myers Squibb
Phase 3
3,040
London, Southampton, Salford, Bristol, High Wycombe, Kirkcaldy
2025-09-22
Recruiting
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
NCT07157787Primary Membranous Nephropathy
Alexion Pharmaceuticals, Inc.
Phase 2
30
Cambridge, Leicester, London, Salford
2025-09-19
Recruiting
PMCF Study of the Axonics SNM System Model 5101 (R20) for the Indication of OAB
NCT06789406Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Overactive Bladder (OAB)
Axonics, Inc.
Not applicable
55
Bradford, Wakefield, Leeds, London
2025-09-18
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
NCT07190222Chronic Obstructive Pulmonary Disease
Sanofi
Phase 3
942
Milton Keynes, London, Southampton, Salford, Chertsey, Reading, Rotherham
2025-09-17
Recruiting
Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)
NCT07176689Desmoid Tumor, Aggressive Fibromatosis
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Phase 4
50
Cambridge, London, Manchester
2025-09-17
Recruiting
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578Alzheimers Disease
Hoffmann-La Roche
Phase 3
800
Bradford, Bristol, Chertsey, London, Newcastle, York
2025-09-17
Recruiting
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
NCT07091630Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
argenx
Phase 3
160
Nottingham, London, Salford
2025-09-16
Recruiting
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
NCT07190209Chronic Obstructive Pulmonary Disease
Sanofi
Phase 3
942
Bristol, London, Leicester, Harrow, Oxford, Worthing, Bradford
2025-09-16
Recruiting
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
NCT07047144Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3
Scholar Rock, Inc.
Phase 2
52
Leeds
2025-09-15
Recruiting
A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
NCT06806592Interstitial Lung Diseases, Systemic Autoimmune Rheumatic Diseases Associated Interstitial Lung Diseases
Boehringer Ingelheim
Phase 3
400
Antrim, Bath, Birmingham, Leeds, London, Londonderry, Luton, Preston
2025-09-13
By invitation
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 Who Have Completed MEX-DM-302 Study.
NCT06549400Myotonic Dystrophy
Lupin Ltd.
Phase 3
176
London
2025-09-12
Recruiting
A 16-week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream 20 mg/g in Adult Participants With Mild to Severe Palmoplantar Pustulosis
NCT07013201Palmoplantar Pustulosis
LEO Pharma
Phase 2
135
Bristol, London, Newcastle upon Tyne, Salford, Stourbridge
2025-09-11
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868Breast Neoplasms
Bristol-Myers Squibb
Phase 2/3
600
Truro, London, Belfast, Manchester, Nottingham
2025-09-11
Recruiting
A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
NCT06919965Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC
Phase 3
220
Cottingham, London, Southampton, Stevenage, Surrey
2025-09-10
Recruiting
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
NCT06855771Carcinoma, Non-Small-Cell Lung
Bristol-Myers Squibb
Phase 2
182
Birmingham, London, Newcastle upon Tyne
2025-09-09
Recruiting
European Real-World Registry for Use of the Ion Endoluminal System
NCT06923774Pulmonary Nodule, Lung Cancer
Intuitive Surgical
Observational
1,200
London, Manchester
2025-09-09
Recruiting
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
NCT07011719Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Arcus Biosciences, Inc.
Phase 3
720
Cambridge, Cottingham, Exeter, Glasgow, Leeds, London, Manchester, Newcastle upon Tyne
2025-09-08
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
BeOne Medicines
Phase 3
500
Brighton, Canterbury, Norwich, Oxford, Roundhay, Salisbury
2025-09-04
Recruiting
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
NCT07157774Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)
Eli Lilly and Company
Phase 3
10,450
Belfast, Birmingham, Blackpool, Bodelwyddan, Bradford on Avon, Bristol, Bromborough, Enfield
2025-09-02
Recruiting
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
NCT07136467Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa
AbbVie
Observational
2,795
London, Oxford, Leeds, Wakefield, Belfast, Cardiff, Walsall, Wolverhampton
2025-09-02
Recruiting
A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease
NCT06984627Graves' Disease
Sanofi
Phase 2
30
Milton Keynes, Newcastle upon Tyne
2025-09-02
Recruiting
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT07164443Metastatic Castration-resistant Prostatic Neoplasms
Janssen Research & Development, LLC
Phase 3
1,203
Birmingham, London, Manchester, Sutton
2025-09-02
Recruiting
Atropine Eyedrops for Myopia Progression in Children and Adolescents (MODERATO STUDY)
NCT07028827Myopia
Ocus Innovation Ireland Limited
Phase 3
234
Belfast, Birmingham, London
2025-09-01
Not yet open
Study to Assess Remote Imaging System to Monitor Diabetic Foot Ulcers
NCT07013448Diabetic Foot Ulcer, Diabetic Foot Ulcer (DFU)
Medical Intelligence Group
Observational
40
Ashton-under-Lyne
2025-09
Recruiting
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45
NCT07038824Duchenne Muscular Dystrophy (DMD)
Entrada Therapeutics, Inc.
Phase 1/2
24
Leeds, Liverpool, London, Manchester, Oxford
2025-08-30
Recruiting
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
NCT06960213Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
ADARx Pharmaceuticals, Inc.
Phase 3
90
Guildford, Cambridge, Cardiff, London, Southampton
2025-08-28
Recruiting
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
NCT06989359IgAN, C3G, Complement-mediated Kidney Disease, IgA Nephropathy (IgAN)
ADARx Pharmaceuticals, Inc.
Phase 2
45
Leicester, Newcastle upon Tyne
2025-08-28
Recruiting
A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)
NCT07200908Chronic Hepatitis D Infection
Mirum Pharmaceuticals, Inc.
Phase 3
172
Birmingham, London, Manchester, Cottingham
2025-08-27
Recruiting
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07043400Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
BeOne Medicines
Phase 3
351
Cambridge, Dundee, Metropolitan Borough of Wirral
2025-08-27
Recruiting
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
NCT06982521PIK3CA Mutation, HER2- Negative Breast Cancer, Hormone Receptor Positive Tumor, Breast Cancer
Relay Therapeutics, Inc.
Phase 3
540
Bath, Cardiff, London, Manchester, Swindon, Truro
2025-08-26
Recruiting
BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies
NCT07160244Healthy
Pfizer
Phase 3
6,000
Bristol, London, Truro, Southampton, Manchester, Oxford, Shropshire, Leeds
2025-08-25
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
argenx
Phase 3
218
Salford, Leeds, London
2025-08-22
Recruiting
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
NCT07151040Solid Tumor, Colorectal Cancer (CRC), Squamous Cell Carcinoma of Head and Neck, Non-Small Cell Lung Cancer (NSCLC)
One-carbon Therapeutics AB
Phase 1/2
43
Newcastle upon Tyne
2025-08-22
Recruiting
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
NCT07018713Chronic Migraine
Merz Therapeutics GmbH
Phase 3
780
Stoke-on-Trent
2025-08-21
Recruiting
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
NCT07018700Episodic Migraine
Merz Therapeutics GmbH
Phase 3
990
Stoke-on-Trent
2025-08-21
Recruiting
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
NCT07058077Heterozygous Familial Hypercholesterolemia (HeFH)
Merck Sharp & Dohme LLC
Phase 2/3
153
Birmingham, Sheffield, Southampton
2025-08-21
Recruiting
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT07090499Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 1
540
London, Manchester
2025-08-20
Recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
Astellas Pharma Global Development, Inc.
Phase 2
218
London
2025-08-19
Active, closed
An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)
NCT06961344Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Tisento Therapeutics
Phase 2
44
London, Newcastle upon Tyne
2025-08-18
Recruiting
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
NCT07081646Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis, Amyloidosis
Alexion Pharmaceuticals, Inc.
Phase 1/2
91
London
2025-08-18
Recruiting
e-Sense® Normal Values of Urodynamic Pressures Using e-Sense® Catheters
NCT06905808Lower Urinary Track Symptoms, Urodynamic Exam
Laborie Medical Technologies Inc.
Observational
40
Bristol
2025-08-15
Recruiting
Haemdall: Developing a Quantitative MRI Biomarker of Infratentorial Superficial Siderosis of the Central Nervous System
NCT07098650Superficial Siderosis
Perspectum
Observational
50
Oxford
2025-08-14
Recruiting
FiH Safety and Feasibility Study Assessing Intra-articular Administration of aeGF in Patients With Knee Osteoarthritis
NCT06690710Osteoarthritis, Knee
Scarcell Therapeutics S.A.S.
Phase 1
15
Oxford
2025-08-14
Recruiting
Open-label Extension Study in Participants With Early Alzheimer's Disease
NCT07105709Alzheimer's Disease
GlaxoSmithKline
Phase 2
220
Birmingham, Bristol, London
2025-08-14
Recruiting
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06948318Immune Thrombocytopenic Purpura (ITP)
Takeda
Phase 3
150
Leicester, Southampton, Southwark, Liverpool, Glasgow, Stoke-on-Trent, Leeds, London
2025-08-14
Recruiting
Phase 1 Study of ADX-626 in Healthy Participants
NCT07081503Healthy Adult Participants
ADARx Pharmaceuticals, Inc.
Phase 1
44
London
2025-08-12
Recruiting
The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
NCT06975865Sickle Cell Disease
Sanofi
Phase 3
192
London
2025-08-12
Recruiting
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
NCT07070232Advanced Solid Tumor
BioNTech SE
Phase 1/2
1,438
Birmingham, Cardiff, Glasgow, Liverpool, London, Manchester, Newcastle upon Tyne, Southampton
2025-08-12
Recruiting
Focused Orticumab Research for Treating Inflammation in Coronary Arteries
NCT06927739Acute Coronary Syndromes, Coronary Arterial Disease (CAD), Inflammation, Heart Disease
Abcentra
Phase 2
240
London, Manchester, Oxford, Bath, Sheffield
2025-08-11
Recruiting
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
NCT07099898Neoplasms, Lung
GlaxoSmithKline
Phase 3
420
London, Portsmouth, Truro
2025-08-11
Recruiting
Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular Hemolysis
NCT06449001Paroxysmal Nocturnal Hemoglobinuria, PNH, Extravascular Hemolysis
Alexion Pharmaceuticals, Inc.
Phase 3
6
Leeds, London
2025-08-11
Recruiting
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
NCT06979596Malignant Neoplasm
Merck Sharp & Dohme LLC
Phase 2
250
East Sussex, Truro, London, Edinburgh, Birmingham, Manchester
2025-08-11
Recruiting
Longitudinal Phenotyping and Endotyping Study in Adult Patients With Mild, Moderate, or Severe Asthma
NCT07189806Asthma (Diagnosis)
Hvivo
Observational
250
London
2025-08-08
Recruiting
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
NCT07094516Alzheimer's Disease
Novartis Pharmaceuticals
Phase 2
407
Edinburgh, Oxford, Aberdeen, London, Newcastle upon Tyne, Salford, Southampton
2025-08-07
Recruiting
A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism
NCT07007793Primary Hyperaldosteronism
AstraZeneca
Phase 3
250
Cambridge, Cardiff, Dundee, London
2025-08-07
Recruiting
Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
NCT06699849Sickle Cell Disease Vaso-occlusive Crisis
CSL Behring
Phase 2
70
London
2025-08-07
Recruiting
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
NCT07088068Type 1 Diabetes Mellitus
Sanofi
Phase 3
723
Cambridge, Dundee, London, Glasgow, Bath, Guildford, Leeds, Reading
2025-08-06
Recruiting
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
NCT06952803Prostate Cancer
AstraZeneca
Phase 3
700
Aberdeen, Bristol, Cambridge, Edinburgh, Exeter, Glasgow, Greater London, Guildford
2025-08-06
Active, closed
Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease
NCT06876363X-Linked Chronic Granulomatous Disease
Ensoma
Phase 1/2
15
London
2025-08-05
Active, closed
A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
NCT07142811Viral Hepatitis
Vir Biotechnology, Inc.
Phase 2
100
London, Manchester, Nottingham
2025-08-05
Recruiting
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
NCT07062965Breast Cancer
Pfizer
Phase 3
400
Taunton
2025-08-05
Recruiting
Obe-cel in Refractory Progressive Forms of Multiple Sclerosis
NCT07139743Progressive Multiple Sclerosis
Autolus Limited
Phase 1
18
Cambridge, Edinburgh, London, Sheffield
2025-08-04
Recruiting
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
NCT07044336Endometrial Cancer, Malignant Solid Tumour
AstraZeneca
Phase 3
800
Bebington, Canterbury, Derby, London, Manchester, Northwood, Truro
2025-08-01
Not yet open
Clinical Performance Study of Microbio InfectID-BSI for Detection of Bacteria and Yeast With Patient Blood Samples
NCT06531031Bloodstream Infection, Sepsis, Septic Shock
Microbio Co Ltd
Observational
1,500
Bristol
2025-08
Active, closed
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
NCT07029711Severe Alopecia Areata
Pfizer
Phase 3
208
Brighton, London
2025-07-31
Recruiting
GB-PRIME: An Early Feasibility Study of a Precise Robotically Implanted Brain-Computer Interface for the Control of External Devices
NCT07127172Tetraplegia/Tetraparesis, Quadriplegia, Quadriplegia/Tetraplegia, Cervical Spinal Cord Injury
Neuralink Corp
Not applicable
7
London, Newcastle upon Tyne
2025-07-31
Recruiting
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
NCT07094113KRAS Altered Advanced or Metastatic Solid Tumors
Amgen
Phase 1
434
London, Sutton
2025-07-31
Rows per page Showing 501–600 of 2847
Previous 4 5 6 7 8 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site. Derived from ClinicalTrials.gov. Retrieved 22 September 2026. https://priyalifescience.com/clinical-trials-uk?page=6

Query this register directly
GET /api/trials?country=uk&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the UK Pharma Salary Guide, or see the Ireland, EU and USA registers.